XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma | MicrobiomeTrials
XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2024-09-19Est. Completion: 2028-07-01
Enrollment target: 73 participants
Locations
Northwestern University, Chicago, Illinois, United States
Advanced Dedifferentiated LiposarcomaAdvanced LeiomyosarcomaAdvanced Soft Tissue SarcomaMetastatic Dedifferentiated LiposarcomaMetastatic LeiomyosarcomaMetastatic Soft Tissue SarcomaStage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
This phase I/II trial tests the side effects and best dose of abemaciclib when added to gemcitabine and compares the eff…
Houston, United StatesEst. completion Jan 31, 2027